Generated by AI
Akari Therapeutics Plc ADR is an oncology biotechnology company focused on developing antibody-drug conjugates designed to deliver cancer-killing payloads directly to tumor cells. The company’s current work centers on its ADC discovery platform, which combines targeted antibodies with novel RNA spliceosome-modulating payloads to create candidates aimed at solid tumors. Its lead program, AKTX-101, is a preclinical TROP2-targeted ADC being studied across multiple tumor types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, and prostate cancers. Akari Therapeutics also maintains a broader research focus on advanced therapies for autoimmune and inflammatory diseases. As an ADR issuer, Akari Therapeutics Plc provides investors access to its ordinary shares through a U.S.-traded depositary receipt structure while the company advances its biotechnology programs from its headquarters in Tampa, Florida.
Website401 East Jackson Street
Tampa, FL, 33602
United States
The latest articles about AKTX.
Summary of Jul 7's posts. Generated by AI.
Summary of May 29's posts. Generated by AI.
Summary of May 29's posts. Generated by AI.
Investors talking about AKTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.